title: Predicting benefit from anti-angiogenic agents in malignancy.
abstract: A high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from an ever-expanding list of expensive new anticancer agents. However, biomarkers of response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic drugs. This discussion will focus on both preclinical and clinical research to identify biomarkers for anti-angiogenic therapies that can inform dosing, early clinical benefit, initial drug choice, emerging resistance and second-line treatments.
authors.affiliation: Academic Unit of Pathology, Leeds Institute for Molecular Medicine, University of Leeds, UK. adrianjubb@gmail.com
authors.forename: Adrian M
authors.initials: AM
authors.lastname: Jubb
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Oates
authors.forename: Scott
authors.initials: S
authors.lastname: Holden
authors.forename: Hartmut
authors.initials: H
authors.lastname: Koeppen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor